1. Home
  2. BMBL vs CUVL Comparison

BMBL vs CUVL Comparison

Compare BMBL & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bumble Inc.

BMBL

Bumble Inc.

N/A

Current Price

$2.83

Market Cap

417.4M

Sector

Technology

ML Signal

N/A

Logo Clinuvel Pharmaceuticals Limited American Depositary Shares

CUVL

Clinuvel Pharmaceuticals Limited American Depositary Shares

N/A

Current Price

$6.25

Market Cap

374.2M

Sector

Miscellaneous

ML Signal

N/A

Company Overview

Basic Information
Metric
BMBL
CUVL
Founded
2014
N/A
Country
United States
Australia
Employees
N/A
16
Industry
Computer Software: Prepackaged Software
Miscellaneous
Sector
Technology
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
417.4M
374.2M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
BMBL
CUVL
Price
$2.83
$6.25
Analyst Decision
Hold
Analyst Count
13
0
Target Price
$4.46
N/A
AVG Volume (30 Days)
2.9M
13.3K
Earning Date
05-05-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$965,658,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.54
$5.95
52 Week High
$7.32
$8.20

Technical Indicators

Market Signals
Indicator
BMBL
CUVL
Relative Strength Index (RSI) 55.25 40.60
Support Level $2.63 N/A
Resistance Level $2.92 $6.82
Average True Range (ATR) 0.12 0.42
MACD 0.02 -0.11
Stochastic Oscillator 98.55 13.33

Price Performance

Historical Comparison
BMBL
CUVL

About BMBL Bumble Inc.

Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company operates as one operating segment with revenue derived in the form of recurring subscriptions and in-app purchases. The company operates in USA, which derives maximum revenue; and Rest of the World.

About CUVL Clinuvel Pharmaceuticals Limited American Depositary Shares

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Share on Social Networks: